Melanoma And Other Skin Cancers
The guidelines address biopsy techniques and histopathologic assessment, staging of tumors, surgical and nonsurgical management, follow-up, prevention of recurrence, and advanced disease management.
The percentage of PD-L1-positive cells was higher in the tumor parenchyma in desmoplastic melanomas than in non-desmoplastic melanomas (P=0.04).
The major efficacy outcome measure was RFS, defined as the time between the randomization date and the date of first recurrence (local, regional, or distant metastasis), new primary melanoma, or death from any cause, whichever occurs first.
The researchers found that ulixertinib exposure was dose-proportional to the RP2D and almost completely inhibited ERK activity in whole blood.
SCC was revealed accompanying AC in 14 patients in postoperative biopsy; four patients in the AC-only group had SCC in situ.
Gorlin Syndrome is a rare, genetic disease characterized by mutations in the tumor suppressor gene encoding Patched1.
The researchers recommend that clinicians provide counseling on sun protection behaviors for anyone with fair skin aged 6 months to 24 years, including parents of young children with fair skin (B recommendation).
The researchers found that the use of propranolol at the time of diagnosis was significantly inversely linked to melanoma recurrence after adjustment for known prognostic factors, with about an 80% reduction in risk for propranolol users.
The researchers found that the estimated 3-year rate of relapse-free survival was 58% in the combination-therapy group and 39% in the placebo group at a median follow-up of 2.8 years.
The researchers found that the 12-month rate of recurrence-free survival was 70.5 and 60.8% in the nivolumab and ipilimumab groups, respectively, at a minimum follow-up of 18 months.
The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.
A Phase 2, single-arm, open-label clinical trial, EMPOWER-CSCC 1, is now enrolling patients with metastatic CSCC and locally advanced and unresectable CSCC.
The researchers found that, as determined by the cell viability assay, ultraviolet (UV)-induced keratinocyte death was attenuated by myricetin in a dose-dependent manner.
A population pharmacokinetic analysis (n=565) showed that Yervoy exposure in patients aged ≥12 years was similar to that in adults at the approved 3mg/kg dose given intravenously (IV) over 90 minutes every 3 weeks for a total of doses.
Compared to controls, the researchers found that male mice consuming red tomato diets or pooled tomato diets had significantly lower tumor number (1.73 ± 0.50 and 2.03 ± 0.45, respectively, versus 4.04 ± 0.65).
The researchers found that, compared with controls, patients with Parkinson's disease had a 3.8-fold increased likelihood of having preexisting melanoma, while patients with melanoma had a 4.2-fold increased risk of developing Parkinson's disease.
The researchers found that 58% of the 526 randomized patients experienced disease progression, including 28 and 72% in the TBP and non-TBP groups.
The approval for Tafinlar and Mekinist combination therapy was based on a Phase 2 international, multicenter, 3-cohort, non-randomized, non-comparative, open-label trial (Study BRF113928) in patients with locally confirmed stage IV NSCLC with BRAF V600E mutation.
The association between melanoma among PDE5i users was only statistically significant for male patients with low PDE5i exposure and with low-stage melanoma.
A total of 568 undergraduate females were randomized to either 1 of 3 message conditions visually depicting health effects, appearance damage, or immediate risks, or to a text-only control.
The researchers found that patients with psoriasis had 1.53 times greater risk of developing a malignancy versus patients without psoriasis (P<0.01).
The accelerated approval was based on data from a single-arm study (n=88) in patients with metastatic MCC who were treated with at least one prior chemotherapy regimen.
A sizeable proportion of melanoma survivors still report elevated sun exposure, sunburns, and suboptimal ultraviolet radiation protection behaviors, according to research published online March 2 in Cancer Epidemiology, Biomarkers & Prevention.
The FDA has approved Opdivo (nivolumab; Bristol-Myers Squibb) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-based chemotherapy or for those who have disease progression within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy.
Clinicians and pharmacists who prescribe and fill medications containing the drug are advised to inform patients to avoid exposure to pets.
The burden of melanoma is increasing in the United States, according to a research letter published online in JAMA Dermatology.